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The primary goal of therapy for acute myocardial infarction
is rapid, complete and sustained restoration of infarct-
related artery (IRA) blood flow. Both fibrinolytic and
mechanical restoration of anterograde coronary blood flow
in patients have shown to improve left ventricular function,
reduce infarct size and reduce mortality (1). The benefits of
myocardial reperfusion, including prevention of infarct ex-
pansion, reduction of ventricular remodeling and improve-
ment of electrical stability, are amplified when IRA patency
can be achieved quickly after the onset of symptoms,
particularly in the first 2 hours—a time window that is
particularly challenging for mechanical methods of reperfu-
sion. The Global Use of Strategies to Open Occluded
Arteries trial (GUSTO-I) (2) correlated 90-min patency of
the IRA with mortality reduction, and the Thrombolysis in
Myocardial Infarction (TIMI-I) trial (3) showed that re-
gardless of the fibrinolytic agent used, an occluded IRA
(TIMI flow grade 0 or 1) at 90 min was associated with an
8.9% 30-day mortality rate, and normal flow (TIMI 3) with
a 4% mortality rate. Those with partial perfusion (TIMI
flow grade 2) had an intermediate mortality rate of 7.4%.
Although intravenous fibrinolytic therapy is effective in
improving outcome after a myocardial infarction and can be
administered early to a greater proportion of patients than is
possible with percutaneous coronary intervention, its “effec-
tiveness profile” is disappointing to most cardiologists.
There is a failure to lyse occlusive thrombi in a quarter of
patients; reocclusion occurs in 10% of patients; and incom-
plete reperfusion is present in 30% (4,5). Also, some
patients have contraindications to this treatment. This is
particularly true in the elderly, in whom stroke rates are
high, but the potential benefit of reperfusion is greatest.
Consequently, primary angioplasty has been adopted by
many cardiologists, where facilities exist, as a preferred
means of reperfusion.
The advantages of percutaneous coronary intervention
include immediate visual assessment of reperfusion success
and identification of the entire coronary and ventricular
anatomy. These assessments often obviate the need for
noninvasive testing before hospital discharge and can lead to
an accelerated discharge and recovery of low risk patients.
In our hospital, patients treated with primary angioplasty
usually spend ,24 h in the coronary care unit. Because no
single comparative study has been large enough to quanti-
tate the difference between these two modalities precisely,
the relative benefits of the two strategies still remain
unknown. In a meta-analysis of all the trials of balloon
angioplasty versus thrombolysis, the relative benefit of
primary angioplasty seemed greatest in the elderly and in
those with “high risk” characteristics (6). Along with the
higher IRA patency rate, one study showed that patients
with an open IRA after successful thrombolysis had a lower
ejection fraction and greater enzyme release as compared
with those treated with primary angioplasty, possibly help-
ing to explain this difference (7). The authors hypothesize
that either the induction of a systemic lytic state generates
an injurious milieu that exerts adverse effects on reper-
fused myocardium, or that angioplasty results in a more
rapid and complete restoration of TIMI flow grade 3
rates. Primary angioplasty, however, necessitates use of
the cardiac catheterization laboratory and personnel
equipped and prepared for emergency procedures, trained
interventional cardiologists and surgical back-up avail-
ability. Therefore, it is not a practical therapy for the
majority of patients.
In this issue of JACC, Ross et al. (8) evaluated the
hypothesis that combining the two strategies may, in fact,
be the best treatment. They propose that the two modalities
may actually be complementary. In combining the treat-
ments, the logistical issues of having immediate availability
of the cardiac catheterization laboratory and trained inter-
ventionalists to perform emergency angioplasty, as well as
the limitation of thrombolytic therapy to achieve TIMI flow
grade 3, counteract one another. In the Plasminogen acti-
vator Angioplasty Compatibility Trial (PACT), 606 pa-
tients were randomized to receive a reduced dose of a
short-acting thrombolytic agent (alteplase, GmbH) or pla-
cebo, followed by immediate angiography with angioplasty
if indicated. All patients were treated with aspirin and
heparin. The end points included patency rates on arrival to
the cardiac catheterization laboratory, technical results when
angioplasty was performed, complication rates and left
ventricular function by treatment assignment and time to
restored patency. On an intention-to-treat basis, the
authors (8) found a higher rate of patency in the group
that received an early bolus of alteplase, but no difference
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in resulting left ventricular function, which was normal in
both groups.
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A previous comparison of primary angioplasty with a
full-dose, long-acting, fibrinogen-depleting thrombolytic
agent (streptokinase) cautioned against combination thera-
pies by reporting excessive rates of blood transfusion and
increased no-reflow and acute occlusion after angioplasty in
the thrombolytic group (9). In this much larger study, as
well as in other contemporary ones, it has been clearly
shown that the complication rates, success rates and bleed-
ing rates of rescue angioplasty are equivalent to those in
control studies. This important observation tells us that
there is no reason to hesitate to perform angiography and
interventional procedures in patients who have been
recently treated with thrombolysis. The difference found
in earlier studies may be the result of the thrombolytic
regimen used and improvements in angiographic tech-
niques.
The PACT trial reaffirms the time-dependent nature of
the open artery hypothesis: patients who experienced suc-
cessful thrombolysis and TIMI flow grade 3 before angio-
plasty had significantly higher ejection fractions as com-
pared with those who did not.
Ross et al. (8) discuss several limitations of their study,
including the infrequent use of stents (26%) and glycopro-
tein IIb/IIIa inhibitors (5%), which are infrequently used
during percutaneous interventions. Another consideration
was the fact that the majority of the acute infarctions were
lower risk (i.e., nonanterior location and overall normal left
ventricular ejection fractions).
Recent data suggest that combining fibrinolytic agents
(which act on the fibrinous component of a clot) with
glycoprotein IIb/IIIa inhibitors and other anticoagulant
agents (which act on the platelet component of the clot)
may further improve the initial results of fibrinolytic treat-
ment (10–12). Combination therapy allows the use of lower
doses of thrombolytic agents, possibly reducing the risk of
intracranial hemorrhage. Platelet inhibition may also reduce
the risk of early reocclusion after thrombolytic therapy.
Results from trials of adjunct glycoprotein IIb/IIIa inhibi-
tors with full-dose thrombolytic therapy or reduced throm-
bolytic therapy have shown improvements in the rate of
TIMI flow grade 3, with patency rates approaching those
reported with primary angioplasty and no increase in bleed-
ing complications (13,14).
How do we translate the findings of this study to our
clinical practice? The safety and efficacy of combined plate-
let receptor antagonists and fibrinolytic treatment still need
to be defined in future clinical trials. Pretreatment with
abciximab in the emergency department before primary
angioplasty appears to have little, if any, advantage in terms
of “opening arteries” earlier (10). Despite its widespread
occurrence, there has been no proven benefit of routinely
performing angiography in all unselected patients with acute
myocardial infarction. If angiography is to be performed, it
should be done either at the time of hospital admission or in
patients with a reduced ejection fraction or residual isch-
emia. Ross et al. (8) have shown that rescue angioplasty can
be performed earlier at no increased risk to patients receiv-
ing thrombolytic therapy.
For now, those centers routinely performing primary
angioplasty will continue to do so. The search will continue
to identify a more effective lytic regimen that results in equal
initial angiographic results as compared with mechanical
reperfusion. We also need to come to grips with the fact that
it may not be the best care to initially manage “high risk”
patients (e.g., .age 70 years, diabetes, evidence of shock
and anterior location) in all hospitals. Serious complications
from myocardial infarction occur most often in the first
few hours—possibly all such patients should be managed
by the PACT method with initial treatment in the local
medical center or ambulance, and then angiography at
the tertiary care center. We manage severe trauma this
way; shouldn’t we be doing the same for acute myocardial
infarction?
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